Why is your research important and how will it influence the understanding and treatment of MS?
We understand that AHSCT creates a dynamic environment that favours early EBV viral re-emergence before immune reconstitution has occurred. This scenario allows us to parse the role of EBV infection and anti-EBV immunity and its impact on MS relapse by tracking EBV viremia in relation to memory B cell reconstitution and clinical condition.
By understanding how different therapies modulate a patient’s immune system, and correlating this with clinical outcomes, we may be able to develop targeted cellular therapies in the future. My particular interest is in trying to see what the immune responses following treatment tell us about the antigenic drivers of disease.